South America Flat Glass Market Summary, Competitive Analysis and Forecast to 2027
Summary
Flat Glass in South America industry profile provides top-line qualitative and quantitative summary information including: market size (value 2017-22, and forecast to 2027). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market.
Key Highlights
Flat glass is typically used for windows and other applications, including glass tables and doors. It is also known as plate glass and sheet glass. By end-use, the market is segmented into building & construction, automotive, and others. The scope of others segment includes electronics, solar PV, and furniture.
The South American flat glass market had total revenues of $2.9 billion in 2022, representing a compound annual growth rate (CAGR) of 3.9% between 2017 and 2022.
Market consumption volume increased with a CAGR of 3.2% between 2017 and 2022, to reach a total of 4.4 million Tons in 2022.
South America has a share of 2.6% in the global flat glass market. For windows, glass doors, transparent walls, and windscreens, flat glass is a type of glass that was initially created in plane shape.
Scope
Save time carrying out entry-level research by identifying the size, growth, major segments, and leading players in the flat glass market in South America
Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the flat glass market in South America
Leading company profiles reveal details of key flat glass market players’ global operations and financial performance
Add weight to presentations and pitches by understanding the future growth prospects of the South America flat glass market with five year forecasts
Reasons to Buy
What was the size of the South America flat glass market by value in 2022?
What will be the size of the South America flat glass market in 2027?
What factors are affecting the strength of competition in the South America flat glass market?
How has the market performed over the last five years?
What are the main segments that make up South America's flat glass market?
OncoCyte Corp Company Overview
OncoCyte Corp Company Snapshot
OncoCyte Corp Pipeline Products and Ongoing Clinical Trials Overview
OncoCyte Corp – Pipeline Analysis Overview
OncoCyte Corp - Key Facts
OncoCyte Corp - Major Products and Services
OncoCyte Corp Pipeline Products by Development Stage
OncoCyte Corp Ongoing Clinical Trials by Trial Status
OncoCyte Corp Pipeline Products Overview
ALK Resistance Monitoring Assay
ALK Resistance Monitoring Assay Product Overview
Breast Confirmatory BI RADS 3-4 Assay
Breast Confirmatory BI RADS 3-4 Assay Product Overview
Companion Diagnostic Test - Alzheimer’s Disease
Companion Diagnostic Test - Alzheimer’s Disease Product Overview
Companion Diagnostic Test - Amyotrophic Lateral Sclerosis
Companion Diagnostic Test - Amyotrophic Lateral Sclerosis Product Overview
Companion Diagnostic Test - Breast Cancer
Companion Diagnostic Test - Breast Cancer Product Overview
Companion Diagnostic Test - Chronic Fatigue Syndrome
Companion Diagnostic Test - Chronic Fatigue Syndrome Product Overview
Companion Diagnostic Test - Colorectal Cancer
Companion Diagnostic Test - Colorectal Cancer Product Overview
Companion Diagnostic Test - Multiple Sclerosis
Companion Diagnostic Test - Multiple Sclerosis Product Overview
Companion Diagnostic Test - Parkinson’s Disease
Companion Diagnostic Test - Parkinson’s Disease Product Overview
Companion Diagnostic Test - Prostate Cancer
Companion Diagnostic Test - Prostate Cancer Product Overview
Companion Diagnostic Test - Rheumatoid Arthritis
Companion Diagnostic Test - Rheumatoid Arthritis Product Overview
Dense Breast Tissue Confirmatory Test - Breast Cancer
Dense Breast Tissue Confirmatory Test - Breast Cancer Product Overview
Diagnostic Assay - Type I Diabetes Product Overview
Diagnostic Test - Brain Cancer
Diagnostic Test - Brain Cancer Product Overview
Diagnostic Test - Gulf War Illnesses
Diagnostic Test - Gulf War Illnesses Product Overview
Diagnostic Test - Huntington's Disease
Diagnostic Test - Huntington's Disease Product Overview
Diagnostic Test - Lung Cancer
Diagnostic Test - Lung Cancer Product Overview
Diagnostic Test - Ovarian Cancer
Diagnostic Test - Ovarian Cancer Product Overview
Diagnostic Test - Systemic Lupus Erythematous
Diagnostic Test - Systemic Lupus Erythematous Product Overview
Insight ALK ECD Assay
Insight ALK ECD Assay Product Overview
Insight DEPDC1 Screen Assay
Insight DEPDC1 Screen Assay Product Overview
Insight ROS1 Fusion Screen Assay
Insight ROS1 Fusion Screen Assay Product Overview
KIR/KIR-Ligand LDT Assay
KIR/KIR-Ligand LDT Assay Product Overview
Lung Screening Assay
Lung Screening Assay Product Overview
Next-Generation DetermaVu
Next-Generation DetermaVu Product Overview
NGS Lung Panel Test
NGS Lung Panel Test Product Overview
PanC-Dx - Bladder Cancer
PanC-Dx - Bladder Cancer Product Overview
PanC-Dx - Breast Cancer
PanC-Dx - Breast Cancer Product Overview
PanC-Dx - Breast Cancer Clinical Trial
PanC-Dx - Colon Cancer
PanC-Dx - Colon Cancer Product Overview
PanC-Dx - Lung Cancer
PanC-Dx - Lung Cancer Product Overview
PanC-Dx - Prostate Cancer
PanC-Dx - Prostate Cancer Product Overview
Therapeutic Monitoring Test - Pancreatic Cancer
Therapeutic Monitoring Test - Pancreatic Cancer Product Overview
Therasure Transplant Monitor Test - LDT
Therasure Transplant Monitor Test - LDT Product Overview
Tumor Type 4 Assay
Tumor Type 4 Assay Product Overview
OncoCyte Corp - Key Competitors
OncoCyte Corp - Key Employees
OncoCyte Corp - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Recent Developments
OncoCyte Corp, Recent Developments
Mar 31, 2023: Oncocyte Reports Preliminary Fourth Quarter and Full Year 2022 Financial Results and Plans to File Form 12b-25 to Extend Filing Date of Its Form 10-K
Mar 29, 2023: Oncocyte Announces Date Change for Fourth Quarter and Full Year 2022 Earnings Call
Mar 02, 2023: Oncocyte Appoints Joshua Riggs as President and Chief Executive Officer
Nov 30, 2022: Oncocyte Announces the Appointment of Louis E. Silverman as a Member of Its Board of Directors
Nov 30, 2022: Oncocyte Announces Executive Leadership Changes
Nov 10, 2022: Oncocyte Reports Third Quarter 2022 Financial Results
Aug 31, 2022: Oncocyte to Participate at the Lake Street 6th Annual Best Ideas Growth Conference
Mar 28, 2022: Oncocyte to Present New Data Confirming Association of IO Score with Response to Immunotherapy Treatment for Bladder Cancer at the American Association for Cancer Research Annual Meeting 2022
Mar 10, 2022: Oncocyte Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update
Nov 09, 2021: Oncocyte Reports Third Quarter 2021 Financial Results and Provides Corporate Update
Table 32: Dense Breast Tissue Confirmatory Test - Breast Cancer - Product Status
Table 33: Dense Breast Tissue Confirmatory Test - Breast Cancer - Product Description
Table 34: DetermaCNI - Product Status
Table 35: DetermaCNI - Product Description
Table 36: DetermaDx - Product Status
Table 37: DetermaDx - Product Description
Table 38: DetermaIO - Product Status
Table 39: DetermaIO - Product Description
Table 40: DetermaIO - A Randomized, Phase Iii Trial to Evaluate the Efficacy and Safety of Pembrolizumab (Mk-3475) as Adjuvant Therapy for Triple Receptor-negative Breast Cancer with ≫/= 1 Cm Residual Invasive Cancer or Positive Lymph Nodes (Ypn1mi, Ypn1-3) after Neoadjuvant Chemotherapy
Table 41: DetermaIO - Neo-adjuvant Study with the PDL1-directed Antibody in Triple Negative Locally Advanced Breast Cancer Undergoing Treatment with Nab-paclitaxel and Carboplatin
Table 42: DetermaMX - Product Status
Table 43: DetermaMX - Product Description
Table 44: DetermaTx - Product Status
Table 45: DetermaTx - Product Description
Table 46: Diagnostic Assay - Amyloidosis - Product Status